Gilead Sciences CEO on raising full-year guidance due to remdesivir sales

Gilead Sciences raised its full-year profit forecast on Monday, as a recent resurgence in Covid-19 cases boosted demand for its Covid-19 treatment, remdesivir. Gilead Sciences CEO Daniel O'Day joined "Squawk Box" on Monday to discuss.